Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 0.97 |
| ▸ | MEN1 | O00255 | 4/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | NPC1 | O15118 | 2/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | RAB9A | P51151 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.97 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.97 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoxetine SCHEMBL8467346 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL33947 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL570572 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8353 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL1200433 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL3905325 | 0.97 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7081402 | 0.97 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3399076 | 0.97 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8911991 | 0.97 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL17436534 | 0.97 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118206506-A | Novel preparation method of fusidine hydrobromide crystal form alpha | 重庆药友制药有限责任公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-116919920-B | Extended-release microsphere composition of venlafaxine xinafoate as well as preparation method and application thereof | 山东泰合医药科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118056565-A | Pharmaceutical composition containing voathixetine hydrobromide and preparation method thereof | 苏州恩华生物医药科技有限公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-117919185-A | Hydrobromic acid voltammetric acid sitagliptin orally disintegrating tablet and preparation method thereof | 深圳市泛谷药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-114965720-B | Method for determining related substances of hydrobromic acid voltammetric acid | 成都康弘药业集团股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117517496-A | Detection method of benzenesulfonate impurities in voathixetine hydrobromide | 山东京卫制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-115536610-B | Preparation method of vothixetine | 湖南省湘中制药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114075153-B | Preparation method of voathixetine impurity | 成都倍特药业股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-115368318-B | Synthesis method and application of voathixetine | 山东辰龙药业有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116919920-A | Extended-release microsphere composition of venlafaxine xinafoate as well as preparation method and application thereof | 山东泰合医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-6203817-B1 | TRANSDERMAL ADMINISTRATION OF A DRUG SALT OF A NON-ZWITTERIONIC DRUG IS DISCLOSED WHEREIN THE DRUG SALT COMPRISES A COMBINATION OF SURFACE ACTIVITY AND A LOW OCTANOL-WATER PARTITION COEFFICIENT; REDUCED SENSITIVITY | ALZA CORPORATION | 2001-03-20 | — | — | US | disclosed |